Tenax Therapeutics Inc. (TENX)
| Bid | 5.74 |
| Market Cap | 23.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.6M |
| EPS (ttm) | -1.15 |
| PE Ratio (ttm) | -4.86 |
| Forward PE | -2.67 |
| Analyst | Buy |
| Ask | 6 |
| Volume | 20,009 |
| Avg. Volume (20D) | 36,047 |
| Open | 5.74 |
| Previous Close | 5.76 |
| Day's Range | 5.55 - 5.79 |
| 52-Week Range | 2.77 - 7.89 |
| Beta | 1.87 |
About TENX
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertensi...
Analyst Forecast
According to 3 analyst ratings, the average rating for TENX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 186.23% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Tenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsTenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-m...